# Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction

Study · id `cardio:ct-nct01491074` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01491074](<https://clinicaltrials.gov/study/NCT01491074>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01491074

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

## Technical summary

Registry record NCT01491074. Randomized; quadruple masking; primary purpose treatment. Start 2011-08 (registry gives no type); primary completion 2013-11 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 120 participants (enrolled count; ClinicalTrials.gov record NCT01491074, source copy `cardio:ctgov-nct01491074-2014-05-19`, retrieved 2026-10-26)
- Start date: 2011-08 (registry gives no type) (ClinicalTrials.gov record NCT01491074, source copy `cardio:ctgov-nct01491074-2014-05-19`, retrieved 2026-10-26)
- Primary completion: 2013-11 (actual) (ClinicalTrials.gov record NCT01491074, source copy `cardio:ctgov-nct01491074-2014-05-19`, retrieved 2026-10-26)
- Completion: 2014-04 (actual) (ClinicalTrials.gov record NCT01491074, source copy `cardio:ctgov-nct01491074-2014-05-19`, retrieved 2026-10-26)
- Countries: Norway (ClinicalTrials.gov record NCT01491074, source copy `cardio:ctgov-nct01491074-2014-05-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01491074-2014-05-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction
- Condition: Non-ST Elevation Myocardial Infarction
- Intervention (Drug): Tocilizumab 280 mg
- Intervention (Drug): NaCl 0.9% 100 ml
- Lead sponsor: Oslo University Hospital
- Lead sponsor class: OTHER
- Collaborator: St. Olavs Hospital
- Collaborator class: OTHER
- Collaborator: South-Eastern Norway Regional Health Authority
- Collaborator class: OTHER
- Collaborator: University of Oslo
- Collaborator class: OTHER
- Collaborator: Norwegian University of Science and Technology
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Non-ST-elevation heart attack (NSTEMI) (`cardio:nstemi`)
- Registry lists this organization as the lead sponsor: Oslo University Hospital (`cardio:org-oslo-university-hospital`)
- Registry lists this organization as a collaborator: St. Olavs Hospital (`cardio:org-st-olavs-hospital`)
- Registry lists this organization as a collaborator: University of Oslo (`cardio:org-university-of-oslo`)
- Registry lists this organization as a collaborator: Norwegian University of Science and Technology (`cardio:org-norwegian-university-of-science-and-technology`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction (`cardio:pubmed-29961572`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 5d8891fa5a92fbecef68084db99d96569dda660752f2ba0acf2b1464e31dab6d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
